Cardiovascular and biochemical risk factors for incident dementia in the hypertension in the very elderly trial

Journal of Hypertension

Volumn 27, Issue 10, 2009, Pages 2055-2062

  Peters, Ruth ^a   Poulter, Ruth ^a   Beckett, Nigel ^a   Forette, Françoise ^b   Fagard, Robert ^c   Potter, John ^d   Swift, Cameron ^e   Anderson, Craig ^f   Fletcher, Astrid ^g   Bulpitt, Christopher J ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b Groupe Hospitalier Broca Cochin   (France)

^c KU LEUVEN DEPARTMENT OF REHABILITATION SCIENCES   (Belgium)

^d UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^e KING S COLLEGE HOSPITAL   (United Kingdom)

^f King George V Building   (Australia)

^g LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

Aged; Blood pressure; Cognitive decline; Dementia; Hypertension; Older adult; Risk factors

Indexed keywords

CREATININE; GLUCOSE; HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INDAPAMIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PERINDOPRIL;

ADD ON THERAPY; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; CARDIOVASCULAR RISK; CHEMICAL PARAMETERS; CHOLESTEROL BLOOD LEVEL; COGNITION; COGNITIVE DEFECT; CREATININE BLOOD LEVEL; DEMENTIA; DIABETES MELLITUS; GLUCOSE BLOOD LEVEL; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; STROKE;

EID: 70350454756     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e32832f4f02     Document Type: Article

References (65)

1. Forti P, Maioli F, Pisacane N, Rietti E, Montesi F, Ravaglia G. Atrial fibrillation and risk of dementia in nondemented elderly subjects with and without mild cognitive impairment (MCI). Arch Gerontol Geriatr 2007; 44 (Suppl 1):155-165.
2. Mead GE, Keir S. Association between cognitive impairment and atrial fibrillation: a systematic review. J Stroke Cerebrovasc Dis 2001; 10:35-43.
3. Rastas S, Verkkoniemi A, Polvikoski T, Juva K, Niinistö L, Mattila K, et al. Atrial Fibrillation, stroke and cognition: a longitudinal population-based study of people aged 85 and older. Stroke 2007; 38:1454-1460.
4. Rengo F, Acanfora D, Trojano L, Scognamiglio P, Ciaburri F, Ceriello A, et al. Congestive heart failure and cognitive impairment in the elderly. Arch Gerontol Geriatr 1995; 20:63-68.
5. Polidori M, Marvardi M, Cherubini A, Senin U, Mecocci P. Heart disease and vascular risk factors in the cognitively impaired elderly: implications for Alzheimers dementia. Aging Clin Exp Res 2001; 13:231-239.
6. Tilvis R, Kä hönen-Väre M, Jolkkonen J, Valvanne J, Pitkala K, Strandberg T. Predictors of cognitive decline and mortality of aged people over a 10-year period. J Gerontol Med Sci 2004; 59A:268-274.
7. Verhaeghen P, Borchelt M, Smith J. Relation between cardiovascular and metabolic disease and cognition in very old age: cross-sectional and longitudinal findings from the Berlin Aging Study. Health Psychol 2003; 22:559-569.
8. Qiu C, Winblad B, Marengoni A, Klarin I, Fastbom J, Fratiglioni L. Heart failure and risk of dementia and Alzheimers disease. Arch Int Med 2006; 166:1003-1008.
9. Trojano L, Incalzi R, Acanfora D, Picone C, Mecocci P, Rengo F. The CHF Italian Study Investigators. Cognitive impairment: a key feature of congestive heart failure in the elderly. J Neurol 2003; 250:1456-1463.
10. Ivan CS, Seshadri S, Beiser A, Au R, Kase C, Kelly-Hayes, et al. Dementia after stroke: the Framingham study. Stroke 2004; 35:1264-1269.
11. SHEP cooperative research group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated hypertension. JAMA 1991; 265:3255-3264.
12. Pérez-Stable E, Halliday R, Gardiner P, Baron R, Hauck W, Acree M, et al. The effects of propanolol on cognitive function and quality of life: a randomised trial among patients with diastolic hypertension. JAMA 2000; 108:359-365.
13. Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B, et al., for the SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003; 21:875-886. (Pubitemid 36677151)
14. The PROGRESS Collaborative Group. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Intern Med 2003; 163:1069-1075.
15. Forette F, Seux M, Staessen J, Lutgarde T, Birkenhäger W, Babarskiene MR, et al. Prevention of dementia in a randomised double blind placebo controlled systolic hypertension in Europe (Syst-Eur) trial. Lancet 1998; 352:1347-1351.
16. Forette F, Staessen J, Lutgarde T, Birkenhager W. Prevention of dementia. Lancet 1999; 353:236-237.
17. McGuiness B, Passmore T, Bullock R. Blood pressure lowering in patients without prior cerebrovascular disease for prevention of cognitive impairment and dementia (Review). Cochrane Database Syst Rev 2006; Issue 2. Art. No.: CD004034. doi: 10.1002/14651858.CD004034.pub2.
18. Peters R, Beckett N, Forette F, Tuomilehto J, Clarke R, Ritchie C, et al., for the HYVET investigators. Incident dementia and blood pressure lowering in the hypertension in the very elderly trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. Lancet Neurol 2008. doi: 10.1016/S1474-4422(08)70143-1.
19. Debling D, Amelang M, Hasselbach P, Stürmer T. Diabetes and cognitive function in a population-based study of elderly women and men. J Diabetes Complications 2005; 20:238-245.
20. Fontbonne A, Berr C, Ducimetiere P, Alperovitch A. Changes in cognitive abilities over a 4 year period are unfavourably affected in elderly diabetic subjects: results of the epidemiology of vascular aging study. Diabetes care 2001; 24:366-370.
21. Bruce D, Casey G, Grange V, Clarnette R, Almeida O, Foster JK, et al., Fremantle Cognition in Diabetes Study. Cognitive impairment, physical disability and depressive symptoms in older diabetic patients: the Freemantle Cognition in Diabetes Study. Diabetes Res Clin Pract 2003; 61:59-67.
22. Biessels G, Staekenborg S, Brunner E, Brayne C, Scheltens P. Risk of dementia in diabetes mellitus: a systematic review. Lancet 2006; 5:64-74. (Pubitemid 41790697)
23. Akomlafe A, Beiser A, Meigs JB, Au R, Green RC, Farrer LA, et al. Diabetes mellitus and risk of developing Alzheimers disease. Results from the Framingham Study. Arch Neurol 2006; 63:1551-1555.
24. Burns J, Donnelly J, Anderson H, Mayo M, Spencer-Gardner L, Thomas G, et al. Peripheral insulin and brain structure in early Alzheimer disease. Neurology 2007; 69:1094-1104.
25. XuW,Qiu C,Winblad B,FratiglioniL.The effect of borderline diabetesonthe risk of dementia and Alzheimers disease. Diabetes 2007; 56:211-216.
26. World Health Organization (1994). Indicators and strategies for iron deficiency and anemia programmes, report of the WHO/UNICEF/UNU consultation; Geneva Switzerland, 6-10 December 1993.
27. Atti A, Palmer K, Volpato S, Zuliani G, Winblad B, Fratiglioni L. Anemia increases the risk of dementia in cognitively intact elderly. Neurobiol Aging 2006; 27:278-284.
28. BeardC, Kokmen E, OBrien P, Ańia B, MeltonJ. RiskofAlzheimers disease among elderly patients with anemia: population-based investigations in Olmsted county Minnesota. Ann Epidemiol 1997; 7:219-224.
29. Balducci L, Ershler W, Krantz S. Anemia in the elderly: clinical findings and impact on health. Crit Rev Oncol Hematol 2006; 58:156-165.
30. Seliger S, Siscovick D, Stehman-Breen C, Gillen D, Fitzpatrick A, Bleyer A, et al. Moderate renal impairment and risk of dementia among older adults: the cardiovascular health cognition study. J Am Soc Nephrol 2004; 15:1904-1911.
31. Munang L, Starr J, Whalley L. Renal function and cognition in the 1932 Scottish Mental Survey Lothian Cohort. Age Ageing 2007; 36:323-325.
32. Lord C, Chaput J, Aubertin-Leheudre M, Labonte M, Dionne I. Dietary animal protein intake: association with muscle mass index in older women. J Nutr Health Aging 2007; 11:383-387.
33. Atzmon G, Gabriely I, Greiner W, Davidson D, Schechter C, Barzilai N. Plasma HDL levels highly correlate with cognitive function in exceptional longevity. J Gerontol A Biol Sci Med Sci 2002; 57A:M712-M715.
34. Newman G, Bang H, Hussain S, Toole J. Association of diabetes, homocysteine, and HDL with cognition and disability after stroke. Neurology 2007; 69:2054-2062.
35. Reitz C, Tang M, Luchsinger J, Mayeux R. Relation of plasma lipids to Alzheimers disease and vascular dementia. Arch Neurol 2004; 61:705-714.
36. Li G, Shofer J, Kukull W, Peskind E, Tsuang D, Breitner J, et al. Serum cholesterol and risk of Alzheimer disease. Neurology 2005; 65:1045-1050.
37. Fischer P, Zehetmayer S, Bauer K, Huber K, Jungwirth S, Tragl K-H. Relation between vascular risk factors and cognition at age 75. Acta Neurol Scand 2006; 114:84-90.
38. Prospective Studies Collaboration. Blood pressure and vascular mortality by age, sex and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55000 vascular deaths. Lancet 2007; 370:1829-1839.
39. Kalmijn S, Feskens E, Launer L, Kromhout D. Cerebrovascular disease, the apolipoprotein e4 allele, and cognitive decline in a community based study of elderly men. Stroke 1996; 27:2230-2235.
40. Moroney J, Tang M, Berglund L, Small S, Merchant C, Bell K, et al. Low-density lipoprotein cholesterol and the risk of dementia with stroke. JAMA 1999; 282:254-260.
41. Tan Z, Seshadri S, Beiser A, Wilson P, Kiel D, Tocco M, et al. Plasma total cholesterol level as a risk factor for Alzheimer disease. The Framingham study. Arch Intern Med 2003; 163:1053-1057.
42. Shepherd J, Blauw G, Murphy M, Bollen E, Buckley B, Cobbe S, et al., on behalf of the PROSPER study group. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002; 360:1623-1630.
43. Yaffe K, Barrett-Connor E, Lin F, Grady D. Serum lipoprotein levels, statin use, and cognitive function in older women. Arch Neurol 2002; 59:378-384.
44. Gaw A, Murray H, Brown A, for the PROSPER study group. Plasma lipoprotein(a) [Lp(a)] concentrations and cardiovascular events in the elderly: evidence from the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER). Atherosclerosis 2005; 180:381-388. (Pubitemid 41072910)
45. Solfrizzi V, Panza F, Colacicco A, DIntrono A, Capurso C, Torres F, et al., for the Italian Longitudinal Study on Aging Working Group. Vascular risk factors, incidence of MCI, and rates of progression to dementia. Neurology 2004; 63:1882-1891.
46. Kivipelto M, Ngandu T, Fratiglioni L, Viitanen M, Ka reholt I, Winblad B, et al. Obesity and vascular risk factors at midlife and the risk of dementia and Alzheimers disease. Arch Neurol 2005; 62:1556-1560. (Pubitemid 41434560)
47. Rietz C, Luchsinger J, Tang M, Manly J, Mayeux R. Impact of plasma lipids and time on memory performance in healthy elderly without dementia. Neurology 2005; 64:1378-1383.
48. Mielke M, Zandi P, Sjögren M, Gustafson D, Ostling S, Steen B, et al. High total cholesterol levels in late life associated with a reduced risk of dementia. Neurology 2005; 64:1689-1695.
49. Zhang J, Muldoon M, McKeown R. Serum cholesterol concentrations are associated with visuomotor speed in men: findings from the third National Health and Nutrition Examination Survey, 1988-19941-3. Am J Clin Nutr 2004; 80:291-298.
50. Panza F, Dintrono A, Capurso C, Colacicco A, Serpia D, Pilotto A, et al. Lipoproteins, vascular-related genetic factors, and human longevity. Rejuvenation Res 2007; 10:441-458.
51. Hoshino T, Kamino K, Matsumoto M. Gene dose effect of the APOE-e4 allele on plasma HDL cholesterol level in patients with Alzheimers disease. Neurobiol Aging 2002; 23:41-45.
52. Michikawa M. Cholesterol paradox: is high total or low HDL cholesterol level a risk for Alzheimers disease? J Neurosci Res 2003; 72:141-146.
53. Beckett N, Peters R, Fletcher A, Staessen J, Liu L, Dumitrascu D, et al., for the HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008; 358:1887-1898.
54. Bulpitt C, Fletcher A, Beckett N, Coope J, Gil-Extremera B, Forette F, et al. Hypertension in the Very Elderly Trial (HYVET): protocol for the main trial. Drugs Aging 2001; 18:151-164.
55. Peters R, Beckett N, Nunes M, Fletcher A, Forette F, Bulpitt C. A substudy protocol of the hypertension in the very elderly trial assessing cognitive decline and dementia incidence (an ongoing randomised double blind placebo-controlled trial). Drugs Aging 2006; 23:83-92.
56. Arvanitakis K, Schneider J, Wilson R, Li Y, Arnold S, Wang Z, et al. Diabetes is related to cerebral infarction but not to AD pathology in older persons. Neurology 2006; 67:1960-1965. (Pubitemid 44967371)
57. Berg E, Craen A, Biessels G, Gussekloo J, Westendorp R. The impact of diabetes mellitus on cognitive decline in the oldest of the old: a prospective population-based study. Diabetologia 2006; 49:2015-2023.
58. Yamada M, Wong F, Suzuki G.Longitudinal trends of haemoglobin levels in a Japanese population: RERFs adult health study subjects. Eur J Haematol 2003; 70:129-135.
59. Woodman R, Ferrucci L, Guralnik J. Anemia in older adults. Current Opin Hematol 2005; 12:123-128.
60. Donini L, Felice M, Cannella C. Nutritional status determinants and cognition in the elderly. Arch Gerontol Geriatr 2007; Suppl 1:143-153.
61. Thomas V, Hageman P. Can neuromuscular strength and functions in people with dementia be rehabilitated using resistance-exercise training? Results from a preliminary intervention study. J Gerontol 2003; 58A:746-751.
62. Skoog I. Antihypertensive treatment and dementia prevention. Lancet Neurol 2008; 7:664-665.
63. Berg E, Biesselsm G, Craen A, Gussekloo J, Westendorp R. The metabolic syndrome is associated with decelerated cognitive decline in the oldest old. Neurology 2007; 69:979-985.
64. Solomon A, Kareholt I, Ngandu T, Winblad B, Nissinen A, Tuomilehto J, et al. Serum cholesterol changes after midlife and late-life cognition twenty-one-year follow-up study. Neurology 2007; 68:751-756.
65. Stewart R, White L, Xue Q, Launer L. Twenty-six-year change n total cholesterol levels and incident dementia. Arch Neurol 2007; 64:103-107.